Brenda Crowder, MD
Gynecology · Elizabethton, TNNPI 1801865324
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.3% of the total across 103 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 13.0% — the pattern of someone who eats at a lot of different presentations.
Across 103 payments — averaging $16.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$227
- AbbVie$198
- Avion Pharmaceuticals$164
- Amgen$159
- Exeltis, USA Inc.$139
- Biohaven Pharmaceutical Holding Company Ltd.$97
- plus $765 from 24 others
What the payments were for
- Food & beverage$1,65094%
- Education$1006%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 7 | $227 |
| AbbVie | 13 | $198 |
| Avion Pharmaceuticals | 10 | $164 |
| Amgen | 10 | $159 |
| Exeltis, USA Inc. | 8 | $139 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $97 |
| Merck | 6 | $85 |
| Exact Sciences | 5 | $77 |
| Daiichi Sankyo Inc. | 4 | $72 |
| Pfizer | 3 | $46 |
| Lilly USA, LLC | 3 | $42 |
| Biohaven Pharmaceuticals, Inc. | 3 | $38 |
| Amarin Pharma, Inc. | 2 | $35 |
| GSK | 2 | $35 |
| Novo Nordisk | 2 | $32 |
| Therapeuticsmd, Inc. | 2 | $31 |
| AstraZeneca | 2 | $30 |
| Mayne Pharma Commercial LLC | 3 | $28 |
| Medtronic | 1 | $27 |
| Convatec Inc. | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Seqirus USA Inc | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Hologic Sales And Service, LLC | 1 | $15 |
| Vanda Pharmaceuticals Inc. | 1 | $15 |
| Mylan Specialty L.p. | 1 | $13 |
| GRT US Holding, Inc. | 1 | $12 |
| Duchesnay USA Incorporated | 1 | $12 |
How this compares
$1,750 in reported general payments places this provider in the 75th percentile of 57 gynecology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 25 | $27,645 |
| Estradiol | 191 | $8,354 |
| PremarinEstrogens, Conjugated | 14 | $6,200 |
| MinivelleEstradiol | 12 | $2,646 |
| Solifenacin Succinate | 46 | $2,132 |
| ValacyclovirValacyclovir Hcl | 21 | $1,510 |
| Medroxyprogesterone Acetate | 43 | $1,308 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 58 | $1,240 |
| Metronidazole | 19 | $678 |
| Norethindrone | 22 | $410 |
| Clobetasol Propionate | 12 | $383 |
| BalzivaNorethindrone-Ethin. Estradiol | 11 | $374 |
| Fluconazole | 37 | $348 |
| Promethazine Hcl | 14 | $243 |
| Oxybutynin Chloride | 12 | $166 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $227 | $27,64525 claims |
| PfizerPremarin | $46 | $6,20014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 57 gynecology providers in Tennessee.
Other gynecology in Elizabethton
- Jeffrey DellKnoxville$8K
- Tobias LimpergNashville$8K
- Susan WebbKnoxville$7K
- April SanchezCollierville$6K
- Todd BorenChattanooga$5K
- Ted AndersonNashville$3K
- Joseph PorteraChattanooga$3K
- Tracie TraverMaryville$3K
- Barbara NylanderNashville$3K
- Carol LynnCollierville$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.